FIGS (FIGS) is back in focus after first quarter revenue and profitability topped Wall Street expectations, and the stock rose 6.5% alongside broader consumer discretionary gains linked to easing bond yields and lower oil prices.

Beyond the post earnings jump, FIGS has a 1 year total shareholder return of about 175% alongside a 3 month share price return of 10.68%. However, the 1 month share price return fell 21.81%, suggesting momentum is consolidating after a strong run.

If this kind of move has you thinking about what else is gaining attention, it could be worth scanning for other healthcare related AI opportunities through our 33 healthcare AI stocks

With FIGS posting revenue of US$666.10m, net income of US$40.64m and a market cap near US$2.03b, the key question now is whether the recent rally still leaves upside on the table or if the stock already reflects expectations for future growth.

Most Popular Narrative: 72.5% Overvalued

At a last close of $12.44 versus a narrative fair value of $7.21, FIGS is framed as richly priced, with that gap hinging on how its growth story is assessed.

The company, on an absolute basis, is still growing well. Further, it has several growth levers, such as expanding its product range, entering new markets, and leaning into its “TEAMS” offering.

Curious what kind of revenue path and profit margins are baked into that valuation gap? According to julio, the fair value rests on specific growth, profitability, and discount rate assumptions that together form a very particular long term picture.

Result: Fair Value of $7.21 (OVERVALUED)

However, this narrative could be challenged if margin progress stalls or if economic pressure on healthcare professionals limits demand for FIGS’ premium priced products.

Next Steps

With sentiment split between concern and optimism, it makes sense to look at the details yourself and move quickly to form your own view using 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If FIGS has you rethinking your watchlist, now is the time to act and line up a few fresh ideas before the next move in the market.

• Target stability with stocks that pass strict balance sheet and fundamentals checks using the solid balance sheet and fundamentals stocks screener (46 results).
• Spot potential bargains by scanning companies that combine quality metrics with attractive pricing through the 53 high quality undervalued stocks.
• Hunt for future standouts by reviewing the screener containing 20 high quality undiscovered gems before they gain broader attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.